SEC Form 4 · accession 0001209191-17-040882
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Milano
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2017 | A | 5,000 | $0.00 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $13.75 | Jun 15, 2017 | A | 10,000 | A | — | Jun 14, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
- F2This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.